Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

ive webcast, go to Watson's Investor Relations website at http://ir.watson.com.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press release and other company information, visit Watson Pharmaceuticals' website at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the inherent uncertainty associated with financial projections; the impact of competitive products and pricing; successful integration of strategic transactions; the ability to recognize the anticipated synergies and benefits of strategic transactions; variability of revenue mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Seoul Semiconductor announced ... various applications in the lighting market. In ... of this technology in emerging markets such as ... wide range of applications such as streetlight and ... lighting. , First launched in 2005 the Acrich ...
(Date:4/23/2015)... ORLANDO, Fla. , April 23, 2015 ... . releases his book "Age Healthier Live Happier - ... kick off the Age Management Medicine Group Conference at ... - 26, 2015. ",Age Healthier Live Happier, ... looking to avoid over-medication and searching for a higher ...
(Date:4/23/2015)... April 23, 2015  Cryoport, Inc. (OTCBB: CYRX) ... solutions for the life sciences industry, today announced ... logistics solutions within the animal husbandry market by ... to support the shipment of equine semen for ... horse Stallions. Animal husbandry is a ...
(Date:4/23/2015)... April 23, 2015  Metanome, Inc., an industry ... company has changed its name to Diversigen, Inc.  ... as the single commercial source for the myriad ... on the diverse opportunities of the microbiome.  From ... accepts – including those that are difficult to ...
Breaking Biology Technology:Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Metanome Announces Corporate Name Change to Diversigen 2
... to... -- HOERSHOLM, Denmark and SAN DIEGO, Sept. 22 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... type of nanoparticle resembling the six-pointed Star of David ... Israel has been discovered by researchers at the Hebrew University ... The discovery, the researchers say, may lead to new ways ... catalyst to capture the sun,s energy and turn it into ...
... Sept. 21 Ramius Value and Opportunity Advisors LLC, a ... Bioscience, Inc. (Nasdaq: CYPB ) has denied Ramius, ... owns 9.9% of the outstanding shares and has launched a ... not currently own for $4.25 per share in cash.  Ramius ...
Cached Biology Technology:Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 2Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 3Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 5Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 6Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 7Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 8Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 9Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 10New nanomaterial, shaped like Stars of David, discovered at Hebrew University 2New nanomaterial, shaped like Stars of David, discovered at Hebrew University 3Cypress Denies Ramius' Legal Right to Stockholder List Materials 2Cypress Denies Ramius' Legal Right to Stockholder List Materials 3
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Geologists from the University of Leicester propose that humankind has ... end to one epoch of Earths history and marked the ... Williams at the University of Leicester and their colleagues on ... presented their research in the journal GSA Today. In ...
... graduate physics curricula in US universities are sorely in need ... Which Way Forward, to be held January 31 - February ... take a candid look at graduate physics programs and consider ... young physicists for future challenges. The conference, ...
... Mass. - Researchers at the Picower Institute for Learning and ... of Science that they have created a way to see, ... a single neural circuit in a living animal. This ... Neuroscience, and colleagues to see how bypassing a major memory-forming ...
Cached Biology News:Man-made changes bring about new epoch in Earth's history 2New MIT tool probes brain circuits 2
... , Maintenance 112 days/each ... , Immunizations/Boost injections x5 /each ... , Production bleed (25 ml blood ... ~ 100 ml blood (~50 ml serum) x1 each ...
... g protein in 200 l SDS-PAGE Western blotting ... Abelson transformed macrophage cells, whole ... should be stored at -20C ... sample vial should be boiled ...
muscle actin (HUC1-1)...
...
Biology Products: